COMMUNIQUÉS West-GlobeNewswire

Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance

15/11/2017 - 14:00

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK ), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable [...]

MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director

15/11/2017 - 14:00

ORLANDO, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical [...]

Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21

15/11/2017 - 14:00

SAN DIEGO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX ) provides a reminder to stockholders that its previously announced rights offering will remain open until 5:00 PM Eastern Time on [...]

Enrolment of First Cohort Completed with Eighth Participant Dosed in Cynata’s World First Clinical Trial

15/11/2017 - 14:00

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to provide an update on the progress of the clinical [...]

BioSyent Releases Results for Third Quarter and First Nine Months of 2017

15/11/2017 - 14:00

TORONTO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three and nine months ended September 30, 2017. Key highlights include: [...]

Biotricity FDA Submission Update

15/11/2017 - 14:00

REDWOOD CITY, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring [...]

Enzymotec Ltd. Reports Third Quarter 2017 Unaudited Financial Results

15/11/2017 - 13:35

MIGDAL HA’EMEQ, Israel, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY ), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and nutritional products, today reported [...]

Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update

15/11/2017 - 13:35

BEDMINSTER, N.J., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, [...]

Foamix Reports Third Quarter 2017 Financial Results and Provides Business Update

15/11/2017 - 13:00

Conference Call and Webcast on Wednesday, November 15, 2017 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX ) (“Foamix Pharmaceuticals” or [...]

ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference

15/11/2017 - 13:00

YONKERS, N.Y., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ: CFRX ), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug- [...]

Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS

15/11/2017 - 13:00

CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), focused on developing and commercializing drugs to treat [...]

Akers Biosciences Announces Q3 2017 Earnings

15/11/2017 - 13:00

Revenues up 10% as Breathalyzers and Cholesterol Tests Begin to Contribute THOROFARE, N.J, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a [...]

Leap Therapeutics Announces $18 Million Private Placement Offering

15/11/2017 - 13:00

CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq: LPTX ), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a purchase [...]

HealthLynked Corp. Announces Third Quarter 2017 Financial Results

15/11/2017 - 11:00

NAPLES, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB:HLYK) today announced its third quarter 2017 financial results. The Company reported revenue of $480,723, and an operating loss of $512,153 that [...]

Eftilagimod Alpha (LAG-3Ig Or IMP321) Pre-IND Meeting With the FDA

15/11/2017 - 09:11

SYDNEY, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ: PBMD ) (“Prima”) is pleased to announce that it held a Pre-Investigational New Drug Application (pre-IND) meeting with the U.S. [...]

Saniona AB: Saniona publishes its interim report for the third quarter 2017

15/11/2017 - 08:02

PRESS RELEASE November 15, 2017 Financial highlights Jan - Sep 2017 (Jan - Sep 2016) · Net revenues were SEK 16.1 M (69.5 M) · EBIT was SEK -40.6 M (19.2 M) · Earnings per share were SEK -1.58 (0.70) · Diluted earnings [...]

Motif Bio secures up to US$20 million debt financing

15/11/2017 - 08:00

NEW YORK, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has entered [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

15/11/2017 - 07:04

REGULATED INFORMATION GHENT, Belgium, 15 November 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

INNATE PHARMA : Third quarter 2017 report

15/11/2017 - 07:01

Third quarter 2017 report Cash, cash equivalents and financial assets [*] amounting to €195.7 million Robust cash position allows for further investment in portfolio of proprietary immuno-oncology programs Innate Pharma [...]